Merus publications
Web14 apr. 2024 · - Investor call on April 17, 2024 at 6:30 p.m. ET. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 14, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ®), … Web12 apr. 2024 · De koers van Merus NV (Aandeel, OTC) met nieuwsberichten, columns, agenda, forum, technische analyse, fundamentele analyse, opties, turbo's, speeders, sprinters en ...
Merus publications
Did you know?
WebMerus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. ... Publication ID Patent Title Status First Filing Date Technology (CPC) Citations; AU-2024274522-A1: Methods and means for the production of ig-like molecules: Pending: 21-May-2024: Web5 uur geleden · Merus Announces Publication of an Abstract on Petosemtamab Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma for …
Web14 apr. 2024 · Merus N.V. today announced the publication of an abstract for a plenary session oral presentation of interim clinical data on the bispecific antibody petosemtamab … Web28 feb. 2024 · UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Feb. 01, 2024 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology …
Web24 rijen · 17 aug. 2024 · Clinical activity of MCLA-128 (zenocutuzumab), trastuzumab and … Web14 apr. 2024 · April 14, 2024 - 11:10 am. UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 14, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication …
WebMerus Multiclonics. Our Multiclonics ® therapeutics are produced from our proprietary technology platforms, which are able to generate a diverse array of antibody binding …
Web25 apr. 2024 · Merus is the sponsor of the clinical trial, investigating Peto, and certain preclinical work described in the Nature Cancer paper was generated in conjunction with … penn state as a schreyer scholarWeb5 uur geleden · Merus Announces Publication of an Abstract on Petosemtamab Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma for Plenary Session Oral Presentation at the AACR Annual Meeting ... penn state assistant coach salaryWebMerus is an equal employment opportunity employer that does not discriminate on the basis of actual or perceived race, color, religious creed, national origin, sex (including pregnancy, childbirth, and related medical conditions), sexual orientation, age, ancestry, disability or perceived disability, qualified handicap, gender identity, military status, veteran status, … penn state ash wednesdayWeb3 apr. 2024 · Merus Announces Publication of an Abstract on Preclinical Mechanism of Action of MCLA-129 Selected for Poster Presentation at the AACR Annual Meeting 2024. Poster presentation: Tuesday, April 18, 2024, 1:30-5:30 p.m. ET Poster presentation: Tuesday, April 18, 2024, 1:30-5:30 p.m. ET penn state ashraeWeb14 apr. 2024 · Merus Announces Publication of an Abstract on Petosemtamab Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma for Plenary Session Oral Presentation at the AACR Annual Meeting 2024 and Provides a Program and Regulatory Update Published: Apr 14, 2024 - Robust 36% overall response rate (ORR) … toast surveyWeb26 okt. 2024 · Webcast link: available on our website. Dial-in: Toll-free: 1 (800) 715-9871 / International: 1 (646) 307-1963. Conference ID: 1694377. About MCLA-129. MCLA-129 is an antibody-dependent cellular ... penn state ashley adamsWeb5 uur geleden · Merus Announces Publication of an Abstract on Petosemtamab Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma for … toast sub in toaster oven